TGFB1 and systemic lupus erythematosus: Humanized SLE mice (8–12 weeks old NSG mice engrafted with 1×107 PBMCs/mouse from patients with SLE) treated with T cell-targeted NPs loaded with IL-2/TGF-β showed significantly reduced serum levels of human IgG and improved skin morphology (25).